So who with inflamm arthralgias might benefit from abatacept, in terms of delaying RA onset? ALTO study (APIPPRA continuation) 1y abatacept then follow If autoAb x5 (RF, ACPA IgG, IgA, anti-CarP, AAPA): sustained delay of RA If not: benefit only on Rx #ACR25 ABST1678 @RheumNow https://t.co/3Pc5ZLzVf6

• https://x.com/drdavidliew/status/1982890389179896280/photo/1
• https://x.com/drdavidliew/status/1982890389179896280/photo/1
• https://x.com/drdavidliew/status/1982890389179896280/photo/1

Early TNFi treatment leads to -Less D2T at 5 yrs -More sustained remission at 10yrs -Less bDMARD escalation at 5yrs -More DMARD free remission at 5yrs and 10 yrs -20% reduction annual healths costs -11 mo delay in ttmt escalation Safety data were not presented #ACR25 https://t.co/jPMGUGPtqP

• https://x.com/AurelieRheumo/status/1982886011811111053/photo/1
• https://x.com/AurelieRheumo/status/1982886011811111053/photo/1

In case you missed it in @ACR_Journals: HCQ for 1y does not prevent RA development in people with CCP3 >2x ULN, either: - during 1y of treatment - in 2y follow-up https://t.co/gtzNiSmutb but StopRA will give us plenty of insights - data is never wasted #ACR25 ABST1674 @RheumNow https://t.co/DDZib5VGtX

• A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid art…
• https://x.com/drdavidliew/status/1982874509758902603/photo/1

In the IMPACT trial (Abs 0855), certolizumab met its primary endpoint: <20% had an adverse pregnancy outcome (APO) among females w/ APS & prior APO. ✅ 94% live births, all survived to discharge 📈 Median GA: 37 wks (no APO) vs 31 wks (APO) @RheumNow #ACR25

Did we need a 2nd Interception RCT of HCQ in Pre-RA? Unsure but in any case, it does not work either STOPRA CCP3+>=2 ind 71 HCQ and 74 PBO 36 months RA conversion Dr Deane's take: "probably wrong drug rather than wrong timing" #ACR25 @RheumNow #ABSTRACT1674 https://t.co/jysdo8iz7v

• https://x.com/AurelieRheumo/status/1982874833257152964/photo/1

Like PEXIVAS steroid taper, this is something we need an online resource to check each time. Its complicated, but feels "right". @RheumNow #ACR25 https://t.co/QAgSQB9XMQ

• https://twitter.com/Yuz6Yusof/status/1982823893199880429

In a cohort of 269,304 IBD patients, NSAID use showed a small increase in IBD-related hospitalisation (HR 1.08), meeting non-inferiority threshold (HR <1.2). No risk in UC (HR 0.96); modest risk in Crohn’s (HR 1.16). Relooks at the current paradigm of blanket NSAID avoidance in https://t.co/O8MWg1BP50

• https://x.com/synovialjoints/status/1982862356670480474/photo/1

56 pts w/tracheobronchial stenosis in GPA, highly frustrating disease manifestation Not surprising to see severe dx & prior intralesional tx assoc with incidence (ie necessity) of tracheal dilation Leflunomide protective? Have others seen this? #ACR @RheumNow Abstr#1596 https://t.co/djJXnAkxnv

• https://x.com/EBRheum/status/1982860846771437709/photo/1

In a prespecified exploratory analysis of REGENCY trial data by DrRovin et al, Bet. wks 24 and 76: Obinutuzumab ⬇️ LN flares vs. PBO (HR 0.44; p=0.0074) Pts on Obi had less unfavorable kidney outcomes vs. PBO (HR 0.37; p=0.0039) Addtl tx option for LN #ACR25 @RheumNow Abs1521 https://t.co/N5K9Nzh71E

• https://x.com/RHEUMarampa/status/1982844740291952655/photo/1

Simko et al. 6-monthly vs 3-monthly MTX lab monitoring. 3821 patients. Appears to be no difference. Potential for significant cost-savings and reduced burden to patients. @RheumNow #ACR25 Abstr#1370 #ACRbest https://t.co/G3tNQq8qXT

• https://x.com/RichardPAConway/status/1982844488977437109/photo/1

Infection data from SELECT-GCA: Glucocorticoids seem to drive overall infectious risk UPA use associated with higher zoster - vaccinate!! @RheumNow #ACR25 Abst# 0895 https://t.co/ueVbFPxG0Q

• https://x.com/Dr_Brian_MD/status/1982843521112641587/photo/1

Post Hoc analysis from SELECT-GCA Increased rate of herpes zoster for 26wk steroid-UPA 15mg (7.3% vs 4.2% 52wk steroid-plbo) but lower rate of SERIOUS infections (7.9% vs 12.7% 52wk steroid-plbo) Zoster risk is real; steroids are the bigger problem @Rheumnow #ACR25 Abstr#0895 https://t.co/IKzO2J4hLH

• https://x.com/EBRheum/status/1982839959070687309/photo/1
• https://x.com/EBRheum/status/1982839959070687309/photo/1
• https://x.com/EBRheum/status/1982839959070687309/photo/1

Concerns using dupilumab in EGPA due to secondary eosinophilia What about when combined with IL-5 therapy? 16 pt on dupi + IL5 agent - if dupi alone caused eosinophilia -> quelled by IL-5 - no eosinophilia when dupi added to IL-5 - effective but slow @RheumNow #ACR25 Abst 1605

Liraglutide had decreased synovial inflammation and fibrosis in mouse models, however dexamethasone didnt have changes in fibrosis scores Abst#1734 #ACR25 @RheumNow https://t.co/O4JYGtDD5N

• https://x.com/bella_mehta/status/1982837788166017285/photo/1

Analysis from FVSG identified 36pts with anti-rituximab antibodies In AAV, lookout for this in pts who are MPO+ & w/higher CD19 at 6 mos. Worse relapse free survival in both AAV & CRYO! @TerrierBen can you share the prevalence of these abs? #ACR25 @RheumNow #ACRBest abstr#1604 https://t.co/Nyx6JxbvUk

• https://x.com/EBRheum/status/1982837442140148004/photo/1
• https://x.com/EBRheum/status/1982837442140148004/photo/1